Friedberg @ 00:25:48Wrong
healthscience
Results from active clinical trials of Gilead’s antiviral remdesivir for COVID‑19 will be published within approximately two weeks of March 14, 2020 (i.e., by late March 2020), providing more efficacy data.
There are active clinical trials that will be published in the next two weeks on remdesivir, which is this antiviral compound from Gilead...we're going to get more data on that soon.
Explanation
Evidence shows that no clinical trial results for remdesivir in COVID‑19 were published by late March 2020.
- The first substantial human dataset on remdesivir in COVID‑19 was the New England Journal of Medicine study of 53 patients treated under a compassionate‑use program. This was not a randomized trial and was e‑published on April 10, 2020, more than three weeks after March 14.(pubmed.ncbi.nlm.nih.gov)
- The first randomized, double‑blind, placebo‑controlled clinical trial of remdesivir (Wang et al., Hubei, China; NCT04257656) was published in The Lancet with an Epub date of April 29, 2020.(pubmed.ncbi.nlm.nih.gov)
- In addition, Gilead’s own February 26, 2020 press release about its Phase 3 SIMPLE trials stated that results from the ongoing trials in China were expected in April, not March, indicating that even internal expectations were on a longer timeline than “within the next two weeks” from mid‑March.(gilead.com)
- NIH’s large NIAID ACTT‑1 randomized trial reported preliminary positive results publicly and via press in late April 2020, with peer‑reviewed publication in NEJM in May 2020—again, well after the late‑March window.(xinhuanet.com)
Because no remdesivir clinical trial results (randomized or otherwise) were published by late March 2020, Friedberg’s timeline prediction that such results would be published "in the next two weeks" from March 14, 2020 did not come true.